BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback